Company: BDRX
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001214659-25-007913
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-15
Form: 424B3
Chunk 2
---
 on Form F-1 registration statements. The closing is expected to take place on or about May 19, 2025, subject to customary closing
conditions. The Company anticipates receiving gross proceeds of approximately $62,000, before estimated offering expenses.

In the event that the
exercise of Warrants would cause the Holder to exceed the beneficial ownership limitation provisions contained in the applicable Warrants,
the Company shall only issue such number of shares that would not cause the Holder to exceed the maximum amount permitted thereunder,
with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance
with such limitations.

As a condition to reducing
the exercise price of the Warrants, each Holder has agreed (i) to not sell or transfer any Warrant Shares until after May 22, 2025, and
(ii) to the extent the Company calls a general and/or annual general meeting of shareholders during the period the Holder is the owner
of such Warrant Shares, to, among other things, vote or cause to be voted such Warrant Shares in favor of any proposal presented by the
Company at such meeting.

The Company will not
be issuing new warrants to replace the Warrants, and it did not engage a placement agent to facilitate the transaction.

The foregoing descriptions
of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreements, a copy
of which is attached to this Report on Form 6-K as Exhibit 10.1.

The information included in this report on Form 6-K, including Exhibit 10.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of May 2025 is:

| Exhibit No. |     | Description               |
| 10.1        |     | Form of Letter Agreement. |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of